133 related articles for article (PubMed ID: 20649681)
21. Complete correction of renal anemia by recombinant human erythropoietin.
Ludat K; Paulitschke M; Riedel E; Hampl H
Clin Nephrol; 2000 Feb; 53(1 Suppl):S42-9. PubMed ID: 10746805
[TBL] [Abstract][Full Text] [Related]
22. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways.
Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B
J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552
[TBL] [Abstract][Full Text] [Related]
23. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.
Nicholson GC; Tennant RC; Carpenter DC; Sarau HM; Kon OM; Barnes PJ; Salmon M; Vessey RS; Tal-Singer R; Hansel TT
Pulm Pharmacol Ther; 2007; 20(1):52-9. PubMed ID: 16406722
[TBL] [Abstract][Full Text] [Related]
24. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
Sommerburg O; Grune T; Hampl H; Riedel E; Ehrich JH; Siems WG
Clin Nephrol; 2000 Feb; 53(1 Suppl):S23-9. PubMed ID: 10746802
[TBL] [Abstract][Full Text] [Related]
25. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
26. Biocompatibility study based on differential sequestration kinetics of CD14+CD16+ blood monocyte subsets with different dialyzers.
Griveas I; Visvardis G; Sakellariou G; Passadakis P; Thodis I; Vargemezis V; Pavlitou A; Fleva A
Ren Fail; 2006; 28(6):493-9. PubMed ID: 16928619
[TBL] [Abstract][Full Text] [Related]
27. Changes in red blood cells membrane protein composition during hemodialysis procedure.
Costa E; Rocha S; Rocha-Pereira P; Castro E; Miranda V; Faria Mdo S; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Ren Fail; 2008; 30(10):971-5. PubMed ID: 19016148
[TBL] [Abstract][Full Text] [Related]
28. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
29. The effect of high-flux hemodialysis on renal anemia.
Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
[TBL] [Abstract][Full Text] [Related]
30. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW
J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment.
Lisowska KA; Debska-Slizień A; Bryl E; Rutkowski B; Witkowski JM
Artif Organs; 2010 Aug; 34(8):654-62. PubMed ID: 20528849
[TBL] [Abstract][Full Text] [Related]
32. Microinflammation in hemodialysis is related to a preactivated subset of monocytes.
Ramirez R; Carracedo J; Berdud I; Carretero D; Merino A; Rodríguez M; Tetta C; Martín-Malo A; Aljama P
Hemodial Int; 2006 Jan; 10 Suppl 1():S24-7. PubMed ID: 16441864
[TBL] [Abstract][Full Text] [Related]
33. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy.
Costa E; Lima M; Alves JM; Rocha S; Rocha-Pereira P; Castro E; Miranda V; do SF; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
J Clin Immunol; 2008 May; 28(3):268-75. PubMed ID: 18205031
[TBL] [Abstract][Full Text] [Related]
34. Platelet surface receptor activation in patients with chronic renal failure on hemodialysis, peritoneal dialysis and those with successful kidney transplantation.
Ballow A; Gader AM; Huraib S; Al-Husaini K; Mutwalli A; Al-Wakeel J
Platelets; 2005 Feb; 16(1):19-24. PubMed ID: 15763892
[TBL] [Abstract][Full Text] [Related]
35. Randomized controlled pilot study of 2 weeks' treatment with high cutoff membrane for hemodialysis patients with elevated C-reactive protein.
Fiedler R; Neugebauer F; Ulrich C; Wienke A; Gromann C; Storr M; Böhler T; Seibert E; Girndt M
Artif Organs; 2012 Oct; 36(10):886-93. PubMed ID: 22845695
[TBL] [Abstract][Full Text] [Related]
36. Recombinant EPO therapy increases erythrocyte expression of complement regulatory proteins.
Ohi H; Tamano M; Sudo S; Okada N
Am J Kidney Dis; 2003 Jan; 41(1):179-85. PubMed ID: 12500235
[TBL] [Abstract][Full Text] [Related]
37. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease.
Rogacev KS; Seiler S; Zawada AM; Reichart B; Herath E; Roth D; Ulrich C; Fliser D; Heine GH
Eur Heart J; 2011 Jan; 32(1):84-92. PubMed ID: 20943670
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory, degenerative and vascular lesions in long-term dialysed patients.
Vrabie CD; Petrescu A; Waller M; Cojocaru M; Ciocâlteu A; Dina I
Rom J Intern Med; 2009; 47(2):149-59. PubMed ID: 20067165
[TBL] [Abstract][Full Text] [Related]
39. [Plasma macrophage colony-stimulating factor level and changes of monocyte subpopulations in chronic renal failure patients treated with hemodialysis].
Satoh T; Saionji K
Rinsho Byori; 1999 Apr; 47(4):359-64. PubMed ID: 10340010
[TBL] [Abstract][Full Text] [Related]
40. [Lymphocyte subpopulations in maintenance hemodialysis patients receiving recombinant human erythropoietin].
Kaneko Y; Motomiya Y; Arai K; Kagebayashi Y; Okada H; Sasaki K; Yoneda T; Yoshida K; Ozono S; Hirao Y
Nihon Jinzo Gakkai Shi; 1993 Jun; 35(6):743-9. PubMed ID: 8377287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
